fdalawblog.net

Revisión web de fdalawblog.net

FDA Law Blog

 Generado el 30 Marzo 2026 11:08 AM

Resultados antiguos? ACTUALIZAR !

La puntuación es 54/100

Contenido SEO

Título

FDA Law Blog

Longitud : 12

Perfecto, tu título contiene entre 10 y 70 caracteres.

Descripción

where experts go to learn about the FDA

Longitud : 39

Preferiblemente tu descripción meta debe contener entre 70 y 160 caracteres (espacios incluidos). Usa esta herramienta gratuita para calcular la longitu del texto.

Palabras Claves (Keywords)

Muy mal. No hemos encontrado palabras clave (meta keywords) en tu página. Usa este generador de meta tags gratuito para crear tus palabras clave.

Propiedades Meta Og

Bien. Tu página usa propiedades Og (etiquetas og).

Propiedad Contenido
type website
title FDA Law Blog
description where experts go to learn about the FDA
url https://www.thefdalawblog.com/
site_name FDA Law Blog
image https://s0.wp.com/i/blank.jpg
locale en_US

Titulos

H1 H2 H3 H4 H5 H6
15 0 4 0 0 0
  • [H1] Hospital Employee Controlled Substance Diversion Is a Topic at Upcoming IAHSS Conference
  • [H1] Job Opportunity: HPM Seeks Associate Drug Development Attorney
  • [H1] DEA Fine Tunes Power of Attorney and DEA-222 Requirements
  • [H1] No, GRAS Isn’t Just About Vinegar
  • [H1] WEBINAR: Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe – April 14th, 10:00 to 11:00 ET
  • [H1] Job Opportunity: HPM Seeks Junior to Mid-Level Attorney with Healthcare Law Experience
  • [H1] PK Studies in the Crosshairs: FDA Revises Biosimilar Development Guidance
  • [H1] Don’t Just Say “We’ll Fix It”: FDA Wants Real Investigations in Your 483 Response
  • [H1] FDA Signals Potential Updates to SUPAC Guidances—Comments Due June 1, 2026
  • [H1] 6-4-2 Blastoff! FDA’s New NDC Format Coming … in 2033
  • [H1] WEBINAR: Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe – March 17th, 10:00 to 11:00 ET
  • [H1] The Dark Side of PREA . . . . But is There a Way to Churn the Cream Into Butter and Crawl Out? Catch Me If You Can!
  • [H1] HPM to Host Complimentary Webinar on US Regulatory Strategy for MedTech Startups
  • [H1] FDA Guidance Sheds (Some) New Light on 3-Year New Clinical Investigation Exclusivity
  • [H1] Federal Court Preliminarily Enjoins Texas Labeling Law
  • [H3] Search FDA Law Blog
  • [H3] Subscribe
  • [H3] Latest Tweets
  • [H3] Awards & Honors

Imagenes

Hemos encontrado 2 imágenes en esta web.

Bien, la mayoría de tus imágenes tienen atributo alt.

Ratio Texto/HTML

Ratio : 15%

Bien, el ratio entre texto y código HTML de esta página es mayor que 15, pero menor que 25 por ciento.

Flash

Perfecto, no se ha detectado contenido Flash en la página.

Iframe

Muy mal, tienes Iframes en la página, esto significa que el contenido no podrá ser indexado.

Reescritura URL

Bien. Tus enlaces parecen amigables

Guiones bajos en las URLs

Hemos detectado guiones bajos en tus URLs. Deberías usar guiones en su lugar para optimizar tu SEO.

Enlaces en página

Hemos encontrado un total de 162 enlaces incluyendo 16 enlace(s) a ficheros

Ancla Tipo Jugo
- Interna Pasando Jugo
Practices Externo Pasando Jugo
Industries Externo Pasando Jugo
FDA Regulatory Categories Externo Pasando Jugo
Professionals Externo Pasando Jugo
About Us Externo Pasando Jugo
Contact Externo Pasando Jugo
News &amp Events Externo Pasando Jugo
Hospital Employee Controlled Substance Diversion Is a Topic at Upcoming IAHSS Conference Externo Pasando Jugo
Job Opportunity: HPM Seeks Associate Drug Development Attorney Externo Pasando Jugo
DEA Fine Tunes Power of Attorney and DEA-222 Requirements Externo Pasando Jugo
No, GRAS Isn’t Just About Vinegar Externo Pasando Jugo
WEBINAR: Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe – April 14th, 10:00 to 11:00 ET Externo Pasando Jugo
180-Day Exclusivity Tracker Interna Pasando Jugo
FDA Citizen Petition Tracker Interna Pasando Jugo
REMS Tracker (Historical – Not Recently Updated) Interna Pasando Jugo
FDA Legislation Tracker Interna Pasando Jugo
Orange Book Archives Interna Pasando Jugo
ANDA Paragraph IV Patent Certifications List Archives Externo Pasando Jugo
Generic Drug Labeling Carve-Out Scorecard Interna Pasando Jugo
Biosimilars State Legislation Scorecard (Historical – Not Recently Updated)  Interna Pasando Jugo
Big Molecule Watch Blog Externo Pasando Jugo
Bloomberg BNA Health Care Blog Externo Pasando Jugo
Drug and Device Law Blog Externo Pasando Jugo
Eye on FDA Externo Pasando Jugo
FDA Matters Externo Pasando Jugo
Harvard Law Bill of Health Externo Pasando Jugo
IN VIVO Blog Externo Pasando Jugo
Internet Drug News.com Externo Pasando Jugo
Lachman Consultants Blog Externo Pasando Jugo
Medical Devices Today Externo Pasando Jugo
Orange Book Blog Externo Pasando Jugo
Pharma IQ Externo Pasando Jugo
Pharmalot Externo Pasando Jugo
SCOTUS Blog Externo Pasando Jugo
The Volokh Conspiracy Externo Pasando Jugo
WLF Legal Pulse Externo Pasando Jugo
Centers for Medicare & Medicaid Services Externo Pasando Jugo
Drug Enforcement Administration Externo Pasando Jugo
Food and Drug Administration Externo Pasando Jugo
Advertising and Promotion (Federal Trade Commission) Externo Pasando Jugo
Advertising and Promotion (OPDP) Externo Pasando Jugo
Animal Drugs and Feeds Externo Pasando Jugo
Biosimilars Externo Pasando Jugo
Cannabis Externo Pasando Jugo
cGMP Compliance Externo Pasando Jugo
Consumer Product Safety Commission Externo Pasando Jugo
Controlled Substances Externo Pasando Jugo
Cosmetics Externo Pasando Jugo
COVID19 Externo Pasando Jugo
Current Affairs Externo Pasando Jugo
Dietary Supplements Externo Pasando Jugo
Drug Development Externo Pasando Jugo
Drug Enforcement Administration Externo Pasando Jugo
Enforcement Externo Pasando Jugo
FDA News Externo Pasando Jugo
Foods Externo Pasando Jugo
Foods and Dietary Supplements Externo Pasando Jugo
Fraud and Abuse Externo Pasando Jugo
Government Pricing Externo Pasando Jugo
Hatch-Waxman Externo Pasando Jugo
Health Care Externo Pasando Jugo
Health Privacy Externo Pasando Jugo
Import/Export Externo Pasando Jugo
In Vitro Diagnostic Devices Externo Pasando Jugo
Jobs Externo Pasando Jugo
Medical Devices Externo Pasando Jugo
Miscellaneous Externo Pasando Jugo
Orphan Drugs Externo Pasando Jugo
OTC Drugs and Cosmetics Externo Pasando Jugo
Prescription Drugs and Biologics Externo Pasando Jugo
Product Jurisdiction and Combination Products Externo Pasando Jugo
Reimbursement Externo Pasando Jugo
Tissue Products Externo Pasando Jugo
Tobacco Externo Pasando Jugo
Uncategorized Externo Pasando Jugo
Larry K. Houck Externo Pasando Jugo
announced Externo Pasando Jugo
Larry Houck Externo Pasando Jugo
here Externo Pasando Jugo
New Single-Sheet Format for U.S. Official Order Form for Schedule I and II Controlled Substances (DEA Form 222) Externo Pasando Jugo
Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments Externo Pasando Jugo
Ricardo Carvajal Externo Pasando Jugo
proposed rule Externo Pasando Jugo
Food and Dietary Supplement Safety and Regulation Conference Externo Pasando Jugo
Catherine Drew Externo Pasando Jugo
Sara W. Koblitz Externo Pasando Jugo
2026-04-14 – Webinar – Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe | Hyman Phelps registration Externo Pasando Jugo
Job Opportunity: HPM Seeks Junior to Mid-Level Attorney with Healthcare Law Experience Externo Pasando Jugo
PK Studies in the Crosshairs: FDA Revises Biosimilar Development Guidance Externo Pasando Jugo
Fabiola C. Gomez, Ph.D., CMC Regulatory Expert Externo Pasando Jugo
announced Externo Pasando Jugo
final guidance Externo Pasando Jugo
requesting comment Externo Pasando Jugo
According to FDA Externo Pasando Jugo
Don’t Just Say “We’ll Fix It”: FDA Wants Real Investigations in Your 483 Response Externo Pasando Jugo
Kalie E. Richardson Externo Pasando Jugo
Charles D. Snow Externo Pasando Jugo
Anne K. Walsh Externo Pasando Jugo
calls Externo Pasando Jugo
Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection Externo Pasando Jugo
21 CFR 211.192 Externo Pasando Jugo
Nonbinding Feedback After Certain FDA Inspections of Device Establishments Guidance (April 2020) Externo Pasando Jugo
previously Externo Pasando Jugo
ICH Q9 Quality Risk Management Externo Pasando Jugo
ICH Q10 Pharmaceutical Quality System Externo Pasando Jugo
Docket FDA-2025-D-1504 Externo Pasando Jugo
Post-Warning Letter Meetings Under GDUFA Guidance for Industry Externo Pasando Jugo
device Externo Pasando Jugo
FDA Signals Potential Updates to SUPAC Guidances—Comments Due June 1, 2026 Externo Pasando Jugo
notice Externo Pasando Jugo
6-4-2 Blastoff! FDA’s New NDC Format Coming … in 2033 Externo Pasando Jugo
Karla L. Palmer Externo Pasando Jugo
Dara Katcher Levy Externo Pasando Jugo
Final Rule Revising the National Drug Code Format and Drug Label Barcode Requirements Externo Pasando Jugo
900-year supply Externo Pasando Jugo
Proposed Rule Externo Pasando Jugo
current version Externo Pasando Jugo
Frequently Asked Questions (FAQs) by the Pharmaceutical Industry in Preparing for the U.S. DSCSA Externo Pasando Jugo
acknowledges Externo Pasando Jugo
Bernstein Rx Solutions, LLC Externo Pasando Jugo
WEBINAR: Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe – March 17th, 10:00 to 11:00 ET Externo Pasando Jugo
2026-03-17 – Webinar – Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe | Hyman Phelps registration Externo Pasando Jugo
The Dark Side of PREA . . . . But is There a Way to Churn the Cream Into Butter and Crawl Out? Catch Me If You Can! Externo Pasando Jugo
Kurt R. Karst Externo Pasando Jugo
Two Little Mice Externo Pasando Jugo
Pediatric Rule Externo Pasando Jugo
Pediatric Research Equity Act Externo Pasando Jugo
Ass’n of Am. Physicians & Surgeons, Inc. v. United States FDA, 226 F. Supp. 2d 204 (D.D.C. 2002) Externo Pasando Jugo
Pediatric Testing of Prescription Drugs: The Food and Drug Administration’s Carrot and Stick for the Pharmaceutical Industry, 49 Am. U.L. Rev. 739 (2000) Externo Pasando Jugo
guidance Externo Pasando Jugo
according to FDA Externo Pasando Jugo
public list Externo Pasando Jugo
Public Law No. 119-75 Externo Pasando Jugo
2012 Food and Drug Administration Safety and Innovation Act Externo Pasando Jugo
BPCA/PREA Report to Congress Externo Pasando Jugo
FDA’s Anti-Franchising Policy: What Is It and Where Did It Come From? (Mar 4, 2015) Interna Pasando Jugo
2012 Letter Decision Externo Pasando Jugo
HPM to Host Complimentary Webinar on US Regulatory Strategy for MedTech Startups Externo Pasando Jugo
Jennifer Newberger Externo Pasando Jugo
Lisa Baumhardt Externo Pasando Jugo
here Externo Pasando Jugo
FDA Guidance Sheds (Some) New Light on 3-Year New Clinical Investigation Exclusivity Externo Pasando Jugo
Sara W. Koblitz Externo Pasando Jugo
Sarah Wicks Externo Pasando Jugo
New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers Externo Pasando Jugo
here Externo Pasando Jugo
here Externo Pasando Jugo
Federal Court Preliminarily Enjoins Texas Labeling Law Externo Pasando Jugo
Riëtte van Laack Externo Pasando Jugo
previously reported Externo Pasando Jugo
filed a complaint Externo Pasando Jugo
filed a motion for preliminary injunction Externo Pasando Jugo
a preliminary injunction Externo Pasando Jugo
2 Externo Pasando Jugo
3 Externo Pasando Jugo
10 Externo Pasando Jugo
20 Externo Pasando Jugo
Last » Externo Pasando Jugo
Tweets by @fdalawblog Externo Pasando Jugo
Disclaimer Externo Pasando Jugo
Careers Externo Pasando Jugo

Palabras Clave SEO

Nube de Palabras Clave

drug fda guidance exclusivity new approval response clinical ndc product

Consistencia de las Palabras Clave

Palabra Clave (Keyword) Contenido Título Palabras Claves (Keywords) Descripción Titulos
fda 169
drug 90
product 71
exclusivity 62
new 51

Usabilidad

Url

Dominio : fdalawblog.net

Longitud : 14

Favicon

Genial, tu web tiene un favicon.

Imprimibilidad

Genial. Hemos encontrado una hoja de estilos CSS para impresión.

Idioma

Genial. Has declarado el idioma en.

Dublin Core

Esta página no usa Dublin Core.

Documento

Tipo de documento (Doctype)

HTML 5

Codificación

Perfecto. Has declarado como codificación UTF-8.

Validez W3C

Errores : 0

Avisos : 0

Privacidad de los Emails

Atención! Hemos encontrado por lo menos una dirección de correo electrónico en texto plano. Usa este protector antispam gratuito para ocultarla de los spammers.

HTML obsoleto

Etiquetas obsoletas Ocurrencias
<u> 1

Hemos detectado etiquetas HTML obsoletas que ya no se usa. Es recomendable que cambies esas etiquetas por otras similares.

Consejos de Velocidad

Excelente, esta web no usa tablas.
Muy mal, tu web está usando estilos embenidos (inline CSS).
Muy mal, tu página web usa demasiados ficheros CSS (más de 4).
Muy mal, tu sitio usa demasiados ficheros JavaScript (más de 6).
Su sitio web se beneficia del tipo de compresión gzip. ¡Perfecto!

Movil

Optimización Móvil

Icono para Apple
Etiqueta Meta Viewport
Contenido Flash

Optimización

Mapa del sitio XML

¡Perfecto! Su sitio tiene un mapa del sitio en XML.

https://www.thefdalawblog.com/wp-sitemap.xml

Robots.txt

https://fdalawblog.net/robots.txt

¡Estupendo! Su sitio web tiene un archivo robots.txt.

Herramientas de Analítica

¡Perfecto! Su sitio web tiene una herramienta de análisis.

   Google Analytics

PageSpeed Insights

Dispositivo
Categorias

Free SEO Testing Tool

Free SEO Testing Tool es una herramienta seo gratuita que te ayuda a analizar tu web